The importance of context dependent (PTEN status) PI3K/Akt/mTOR signaling inhibition must be taken into consideration during the use of isoform specific or pan-PI3K inhibitors in combination therapies with Sorafenib with respect to resistance in HCC cells. This evidence concerns the gene PIK3CB and hepatocellular carcinoma.